Senzime AB Receives Regulatory Approval for TetraGraph in Mexico

Uppsala, Sweden – July 23, 2025 – Senzime AB, a health care equipment and supply company based in Uppsala, Sweden, has announced that its TetraGraph system has received regulatory approval from the Mexican Secretariat of Health (COFEPRIS). This approval enables Senzime to commence commercialization of its products in the Mexican market, marking a significant milestone for the company.

The TetraGraph system, which specializes in measuring metabolites in biological fluids, is now poised to enter one of the largest economies in the world. This development follows Senzime’s successful entry into the Chilean market, where the company has already secured orders.

Philip Siberg, CEO of Senzime, commented on the achievement, highlighting the strategic importance of the Mexican market for the company’s growth. “Receiving approval in Mexico is a testament to the quality and reliability of our TetraGraph system. It opens up a vast market opportunity for us, and we are excited to expand our presence in Latin America,” said Siberg.

The approval comes at a time when Senzime is experiencing robust growth. In the second quarter of 2025, the company reported a 72% increase in revenue, driven by record sales of TetraGraph systems and doubled volumes of single-use sensors. With over 4,100 systems delivered globally, Senzime continues to strengthen its market position.

Financially, Senzime AB is listed on the Swedish Stock Exchange, with a market capitalization of 861.54 million SEK. The company’s stock closed at 6.25 SEK on July 21, 2025, with a 52-week high of 9.6 SEK and a low of 3.6 SEK. The price-to-earnings ratio stands at -5.84, reflecting the company’s current financial performance.

The approval in Mexico is expected to bolster Senzime’s growth trajectory, providing a significant boost to its international expansion efforts. As the company continues to innovate and expand its product offerings, it remains well-positioned to capitalize on emerging opportunities in the global health care market.